Handelsbanken Fonder AB Sells 124,031 Shares of Boston Scientific Corporation $BSX

Handelsbanken Fonder AB lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 5.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,256,382 shares of the medical equipment provider’s stock after selling 124,031 shares during the quarter. Boston Scientific accounts for 0.7% of Handelsbanken Fonder AB’s investment portfolio, making the stock its 19th largest holding. Handelsbanken Fonder AB owned 0.15% of Boston Scientific worth $220,291,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Steph & Co. bought a new stake in shares of Boston Scientific in the 3rd quarter worth $25,000. Financial Consulate Inc. purchased a new position in Boston Scientific during the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new stake in Boston Scientific in the 2nd quarter worth about $26,000. Finally, United Community Bank increased its stake in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BSX shares. Royal Bank Of Canada cut their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. UBS Group cut their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. The Goldman Sachs Group set a $99.00 price target on shares of Boston Scientific in a report on Thursday, February 5th. Finally, Stifel Nicolaus reduced their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average price target of $108.36.

Boston Scientific Trading Up 3.1%

Shares of BSX opened at $75.77 on Friday. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The business has a 50-day moving average of $87.69 and a 200 day moving average of $95.83. The firm has a market cap of $112.43 billion, a P/E ratio of 39.06, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.